12/15-Lipoxygenase and neurovascular damage following cardiac arrest

心脏骤停后的 12/15-脂氧合酶和神经血管损伤

基本信息

  • 批准号:
    8239055
  • 负责人:
  • 金额:
    $ 37.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ischemic brain damage is a major factor contributing to high rates of both disability and mortality following heart failure. Cardiac arrest leads to selective cell death in both hippocampus and cortex, as well as vascular leakage and edema. Oxidative stress is a major feature of ischemic brain damage, and 12/15-lipoxygenase (12/15-LOX) is one of its main mediators. In this proposal, we plan to investigate the contributions of 12/15- LOX to both vascular damage and neuronal cell death following global ischemia induced by cardiac arrest. We have previously established 12/15-LOX as a major contributor to delayed neuronal cell death and leakage of the blood - brain barrier following transient focal ischemia. In addition, we have elucidated a major cell death pathway centered on 12/15-LOX. Here, we will use mouse models of cardiac arrest and global cerebral ischemia to investigate increased 12/15-LOX expression after cardiac arrest. Our central hypothesis states that increased vascular and neuronal 12/15-LOX exacerbates brain damage by causing oxidative stress, leading to vascular leakage, edema, and the death of neurons. Our preliminary results show that a) expression of 12/15-LOX is increased in a mouse model of cardiac arrest and resuscitation; b) 12/15-LOX co-localizes with MDA2, a marker for oxidative stress, as well as FluoroJade B, a marker for cellular injury; c) these findings can be replicated in a model of global cerebral ischemia; and d) mice in which 12/15-LOX has been genetically deleted show reduced damage after cardiac arrest. We propose to study the consequences of 12/15-LOX up-regulation in mouse models of global ischemia in the following specific aims. In Aim 1, we characterize the expression of 12/15-LOX in a mouse model of cardiac arrest with resuscitation. Besides determining the cell types expressing 12/15-LOX, we will investigate markers of oxidative stress and cellular damage. In addition, we will measure levels of edema and vascular leakage. In Aim 2, we study the protection through 12/15-LOX gene knockout against neural cell death and edema formation in the mouse model of cardiac arrest and resuscitation. In Aim 3, we investigate the protective potential of pharmacologically inhibiting 12/15-LOX with a specific inhibitor, and compare with therapeutic hypothermia treatment. We will determine both short- and long-term outcome, using behavioral tests and histological measures. Severe ischemia and reperfusion injury is associated with cardiac arrest and subsequent cardiopulmonary resuscitation. Elucidating the role of 12/15-LOX in mediating ischemic damage may lead to novel therapeutic options in treating cardiac arrest patients. PUBLIC HEALTH RELEVANCE: Oxidative stress and damage to the brain vasculature are major complications in the aftermath of cardiac arrest, leading to the death of neurons and edema in the brain. 12/15-Lipoxygenase is one of the major mediators of oxidative stress, and we propose to study its role in causing brain injury following cardiac arrest and global brain ischemia. By blocking the activity of 12/15-lipoxygenase, we hope to find new treatment options that benefit survivors of cardiac arrest.
描述(由申请人提供):缺血性脑损伤是心力衰竭后导致高残疾率和死亡率的主要因素。心脏骤停导致海马体和皮质的选择性细胞死亡,以及血管渗漏和水肿。氧化应激是缺血性脑损伤的主要特征,12/15-脂氧合酶(12/15-LOX)是其主要介质之一。在本提案中,我们计划研究 12/15-LOX 对心脏骤停引起的全身缺血后血管损伤和神经元细胞死亡的影响。我们之前已经确定 12/15-LOX 是短暂性局灶性缺血后延迟性神经细胞死亡和血脑屏障渗漏的主要因素。此外,我们还阐明了以12/15-LOX为中心的主要细胞死亡途径。在这里,我们将使用心脏骤停和全脑缺血的小鼠模型来研究心脏骤停后 12/15-LOX 表达的增加。我们的中心假设指出,血管和神经元 12/15-LOX 增加会引起氧化应激,从而导致血管渗漏、水肿和神经元死亡,从而加剧脑损伤。我们的初步结果表明:a) 心脏骤停和复苏小鼠模型中 12/15-LOX 的表达增加; b) 12/15-LOX 与氧化应激标记物 MDA2 以及细胞损伤标记物 FluoroJade B 共定位; c) 这些发现可以在全脑缺血模型中复制; d) 12/15-LOX 基因被删除的小鼠在心脏骤停后表现出较小的损伤。我们建议按照以下具体目标研究 12/15-LOX 上调在小鼠全身缺血模型中的后果。在目标 1 中,我们描述了心脏骤停复苏小鼠模型中 12/15-LOX 的表达。除了确定表达 12/15-LOX 的细胞类型外,我们还将研究氧化应激和细胞损伤的标记物。此外,我们将测量水肿和血管渗漏的程度。在目标 2 中,我们研究了通过 12/15-LOX 基因敲除对心脏骤停和复苏小鼠模型中神经细胞死亡和水肿形成的保护作用。在目标 3 中,我们研究了用特定抑制剂在药理学上抑制 12/15-LOX 的保护潜力,并与低温治疗进行比较。我们将使用行为测试和组织学测量来确定短期和长期结果。严重的缺血和再灌注损伤与心脏骤停和随后的心肺复苏有关。阐明 12/15-LOX 在介导缺血性损伤中的作用可能会为治疗心脏骤停患者带来新的治疗选择。 公众健康相关性:氧化应激和脑血管系统损伤是心脏骤停后的主要并发症,导致神经元死亡和脑水肿。 12/15-脂氧合酶是氧化应激的主要介质之一,我们建议研究其在心脏骤停和全脑缺血后引起脑损伤中的作用。通过阻断 12/15-脂氧合酶的活性,我们希望找到有利于心脏骤停幸存者的新治疗方案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KLAUS VAN LEYEN其他文献

KLAUS VAN LEYEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KLAUS VAN LEYEN', 18)}}的其他基金

A Novel Neuroprotectant to Reduce Ischemic Injury
一种减少缺血性损伤的新型神经保护剂
  • 批准号:
    10576568
  • 财政年份:
    2023
  • 资助金额:
    $ 37.67万
  • 项目类别:
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network
在 SPAN 网络中测试脂氧合酶抑制剂 BPN-27332 作为急性期中风治疗的作用
  • 批准号:
    10671991
  • 财政年份:
    2023
  • 资助金额:
    $ 37.67万
  • 项目类别:
Development of human 12/15-lipoxygenase therapeutics for stroke
开发人类 12/15-脂氧合酶治疗中风的药物
  • 批准号:
    9898504
  • 财政年份:
    2018
  • 资助金额:
    $ 37.67万
  • 项目类别:
Development of human 12/15-lipoxygenase therapeutics for stroke
开发人类 12/15-脂氧合酶治疗中风的药物
  • 批准号:
    9922389
  • 财政年份:
    2018
  • 资助金额:
    $ 37.67万
  • 项目类别:
Novel 12/15 lipoxygenase inhibitors for the treatment of stroke
用于治疗中风的新型 12/15 脂氧合酶抑制剂
  • 批准号:
    8684486
  • 财政年份:
    2014
  • 资助金额:
    $ 37.67万
  • 项目类别:
Novel 12/15 lipoxygenase inhibitors for the treatment of stroke
用于治疗中风的新型 12/15 脂氧合酶抑制剂
  • 批准号:
    8846695
  • 财政年份:
    2014
  • 资助金额:
    $ 37.67万
  • 项目类别:
Effects of Semaphorin 3A on Stroke Recovery
Semaphorin 3A 对中风恢复的影响
  • 批准号:
    8470260
  • 财政年份:
    2011
  • 资助金额:
    $ 37.67万
  • 项目类别:
Effects of Semaphorin 3A on Stroke Recovery
Semaphorin 3A 对中风恢复的影响
  • 批准号:
    8305479
  • 财政年份:
    2011
  • 资助金额:
    $ 37.67万
  • 项目类别:
Effects of Semaphorin 3A on Stroke Recovery
Semaphorin 3A 对中风恢复的影响
  • 批准号:
    8041869
  • 财政年份:
    2011
  • 资助金额:
    $ 37.67万
  • 项目类别:
12/15-Lipoxygenase and neurovascular damage following cardiac arrest
心脏骤停后的 12/15-脂氧合酶和神经血管损伤
  • 批准号:
    8318072
  • 财政年份:
    2005
  • 资助金额:
    $ 37.67万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了